MARKET

IMMP

IMMP

Immutep
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.270
-0.030
-2.31%
After Hours: 1.270 0 0.00% 17:25 08/14 EDT
OPEN
1.270
PREV CLOSE
1.300
HIGH
1.290
LOW
1.260
VOLUME
156.67K
TURNOVER
--
52 WEEK HIGH
3.100
52 WEEK LOW
0.5300
MARKET CAP
49.38M
P/E (TTM)
-0.4076
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IMMP stock price target is 3.491 with a high estimate of 4.987 and a low estimate of 1.995.

EPS

IMMP News

More
Immutep Granted U.S. Patent For Eftilagimod Alpha In Chemo-Immunotherapy Combination
Benzinga · 4d ago
Immutep shares are trading higher after the company announced it has been granted a US Patent for Eftilagimod Alpha in Chemo-immunotherapy combination.
Benzinga · 4d ago
Immutep shares are trading higher after the company announced it has been granted a US Patent for Eftilagimod Alpha in Chemo-immunotherapy combination.
Benzinga · 4d ago
Immutep Granted United States Patent for Eftilagimod Alpha in Chemo-immunotherapy Combination
Immutep Limited (NASDAQ: IMMP) is pleased to announce the grant of a new patent (number 10,736,940) entitled "Combined Preparations for the Treatment of Cancer" by the United States Patent Office.
Benzinga · 4d ago
Immutep Granted United States Patent for Eftilagimod Alpha in Chemo-immunotherapy Combination
Benzinga · 4d ago
Immutep up 52% on U.S. patent covering LAG-3 technology
Nano cap Immunotep Limited (IMMP +51.8%) is up on a healthy 76x surge in volume in reaction to its receipt of a new U.S. patent (No. 10,711,060) covering t
seekingalpha · 07/15 20:04
Mid-Day Market Update: Nasdaq Turns Negative; Immutep Shares Spike Higher
Midway through trading Wednesday, the Dow traded up 0.45% to 26763.36 while the NASDAQ fell 0.25% to 10,462.34. The S&P also rose, gaining 0.39% to 3,210.08.
Benzinga · 07/15 16:12
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent
Benzinga · 07/15 12:30

Industry

Biotechnology & Medical Research
-0.54%
Pharmaceuticals & Medical Research
-0.38%

Hot Stocks

Symbol
Price
%Change

About IMMP

Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.
More

Webull offers kinds of Immutep Ltd stock information, including NASDAQ:IMMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMMP stock methods without spending real money on the virtual paper trading platform.